Maurizio Scaltriti

Citado por

	Total	Desde 2019
Citas	24448	14328
Índice h	74	60
Índice i10	142	127

3200

1600

800

2400

2006200720082009201020112012201320142015201620172018201920202021202220232024131 190 196 383 450 616 833 1001 1030 1174 1145 1235 1366 1869 2489 3142 3018 2829 953

Acceso público

Ver todo

106 artículos

2 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Violeta Serra, PhDPrincipal InvestigatorDirección de correo verificada de vhio.net
Neal RosenProfessor of Pharmacology, Memorial Sloan-Kettering Cancer CenterDirección de correo verificada de mskcc.org
Saverio BettuzziUniversità di Parma Dipartimento DiMeCDirección de correo verificada de unipr.it
Pau CastelNew York University School of MedicineDirección de correo verificada de nyulangone.org
Pedram RazaviMemorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org
Moshe ElkabetsBen-Gurion University of the NegevDirección de correo verificada de bgu.ac.il
Paolo NuciforoMolecular Pathologist, VHIODirección de correo verificada de vhio.net
David M HymanLoxo Oncology, Eli LillyDirección de correo verificada de loxooncology.com
Pieter EichhornCurtin UniversityDirección de correo verificada de curtin.edu.au
David SolitDirector, Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org
Maura DicklerMemorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org
Chandra VermaBioinformatics InstituteDirección de correo verificada de bii.a-star.edu.sg
Federico RojoFundacion Jimenez DiazDirección de correo verificada de fjd.es
Celina Garcia-GarciaPostdoctoral researcher at the Italian Institute of Technology (IIT)Dirección de correo verificada de iit.it
Yosi ShamayAssistant ProfessorDirección de correo verificada de technion.ac.il
Charles RudinChief, Thoracic Oncology, Memorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org
Filippo MontemurroIstituto di Candiolo, FPO-IRCCSDirección de correo verificada de ircc.it
Christina LeslieMemorial Sloan Kettering Cancer CenterDirección de correo verificada de mskcc.org
Poulikos I. PoulikakosIcahn School of Medicine at Mount SinaiDirección de correo verificada de mssm.edu
Gary UlanerHoag Family Cancer Institute, Newport Beach, CaliforniaDirección de correo verificada de hoag.org

Seguir

Maurizio Scaltriti

AstraZeneca

Dirección de correo verificada de astrazeneca.com

Oncology


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
NTRK fusion-positive cancers and TRK inhibitor therapy E Cocco, M Scaltriti, A Drilon Nature reviews Clinical oncology 15 (12), 731-747, 2018	1211	2018
The epidermal growth factor receptor pathway: a model for targeted therapy M Scaltriti, J Baselga Clinical cancer research 12 (18), 5268-5272, 2006	1177	2006
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity S Chandarlapaty, A Sawai, M Scaltriti, V Rodrik-Outmezguine, ... Cancer cell 19 (1), 58-71, 2011	1057	2011
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer M Scaltriti, F Rojo, A Ocaña, J Anido, M Guzman, J Cortes, S Di Cosimo, ... Journal of the National Cancer Institute 99 (8), 628-638, 2007	1029	2007
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations V Serra, B Markman, M Scaltriti, PJA Eichhorn, V Valero, M Guzman, ... Cancer research 68 (19), 8022-8030, 2008	921	2008
The genomic landscape of endocrine-resistant advanced breast cancers P Razavi, MT Chang, G Xu, C Bandlamudi, DS Ross, N Vasan, Y Cai, ... Cancer cell 34 (3), 427-438. e6, 2018	797	2018
HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018	673	2018
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer V Serra, M Scaltriti, L Prudkin, PJA Eichhorn, YH Ibrahim, ... Oncogene 30 (22), 2547-2557, 2011	598	2011
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition YH Ibrahim, C García-García, V Serra, L He, K Torres-Lockhart, A Prat, ... Cancer discovery 2 (11), 1036-1047, 2012	591	2012
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235 PJA Eichhorn, M Gili, M Scaltriti, V Serra, M Guzman, W Nijkamp, ... Cancer research 68 (22), 9221-9230, 2008	585	2008
Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor D Juric, P Castel, M Griffith, OL Griffith, HH Won, H Ellis, SH Ebbesen, ... Nature 518 (7538), 240-244, 2015	574	2015
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling VS Rodrik-Outmezguine, S Chandarlapaty, NC Pagano, PI Poulikakos, ... Cancer discovery 1 (3), 248-259, 2011	513	2011
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity M Scaltriti, C Verma, M Guzman, J Jimenez, JL Parra, K Pedersen, ... Oncogene 28 (6), 803-814, 2009	491	2009
Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial BT Li, R Shen, D Buonocore, ZT Olah, A Ni, MS Ginsberg, GA Ulaner, ... Journal of Clinical Oncology 36 (24), 2532, 2018	479	2018
Targeted drug delivery strategies for precision medicines MT Manzari, Y Shamay, H Kiguchi, N Rosen, M Scaltriti, DA Heller Nature Reviews Materials 6 (4), 351-370, 2021	447	2021
A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion–positive solid tumors A Drilon, R Nagasubramanian, JF Blake, N Ku, BB Tuch, K Ebata, S Smith, ... Cancer discovery 7 (9), 963-972, 2017	382	2017
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients M Scaltriti, PJ Eichhorn, J Cortés, L Prudkin, C Aura, J Jiménez, ... Proceedings of the National Academy of Sciences 108 (9), 3761-3766, 2011	372	2011
Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the hippo pathway Z Li, P Razavi, Q Li, W Toy, B Liu, C Ping, W Hsieh, F Sanchez-Vega, ... Cancer cell 34 (6), 893-905. e8, 2018	363	2018
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes EA Mittendorf, Y Wu, M Scaltriti, F Meric-Bernstam, KK Hunt, S Dawood, ... Clinical Cancer Research 15 (23), 7381-7388, 2009	359	2009
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence C Yang, Z Li, T Bhatt, M Dickler, D Giri, M Scaltriti, J Baselga, N Rosen, ... Oncogene 36 (16), 2255-2264, 2017	350	2017

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores